• Synthetic Viability in ERCC1-Deficient Lung Cancer: p53 and

  2026-07-14

  Heyza et al. systematically dissect the interplay between ERCC1 deficiency and p53 status in lung cancer cells, revealing that p53 loss confers a synthetic viable phenotype under DNA crosslinking stress. Their work clarifies why ERCC1 is an inconsistent biomarker for platinum-based chemotherapy and highlights the complexity of DNA repair dependencies in tumor cell survival.

• Capecitabine in Translational Oncology: Mechanism & Strategy

  2026-07-13

  This article explores Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) as a paradigm-shifting tool for translational cancer research. Bridging mechanistic insights, recent advances in assembloid modeling, and practical protocol guidance, it empowers researchers to unlock new levels of tumor selectivity and therapeutic relevance. Evidence from state-of-the-art models and robust product validation underscores the path toward more predictive, patient-specific oncology workflows.

• Strategic MCL1 Inhibition: Translating S63845 to Cancer Rese

  2026-07-13

  This thought-leadership article explores how the S63845 MCL1 inhibitor reshapes apoptosis research, with mechanistic detail and actionable guidance for translational scientists. Drawing from pivotal studies on BH3 mimetics and integrating lessons from recent literature, the article connects mitochondrial pathway activation with strategies to overcome senescence-associated resistance. Insights into experimental design, competitive positioning, and future clinical translation are provided, with context-rich references and a clear differentiation from standard product overviews.

• Otilonium Bromide: Advancing Translational Cholinergic Resea

  2026-07-12

  Explore the strategic and mechanistic advantages of Otilonium Bromide as a high-purity antimuscarinic agent for translational neuroscience and smooth muscle research. This article synthesizes the latest evidence on cholinergic pathway modulation, experimental best practices, and the compound's emerging relevance for disease modeling, providing actionable guidance for researchers seeking robust, reproducible results.

• Translational Impact of DPP-4 Inhibition: Mechanisms and Str

  2026-07-10

  This article explores how sitagliptin phosphate monohydrate, a potent DPP-4 inhibitor, advances metabolic disease research by bridging mechanistic incretin biology with translational models. It contextualizes recent findings on intestinal stretch and satiety, offers protocol guidance, and frames the compound's unique value in evolving paradigms of type II diabetes treatment research.

• Alosetron as a 5-HT3 Receptor Antagonist in GI Stem Cell Res

  2026-07-09

  Harnessing Alosetron’s selective 5-HT3 antagonism enables high-precision dissection of serotonin-dependent mechanisms in gastrointestinal epithelial polarity and stem cell fate studies. This guide translates recent polarity-pathway breakthroughs into actionable protocols and troubleshooting strategies for translational GI researchers.

• m6A Modification and Antiviral Defense: Insights from Plant–

  2026-07-09

  This study uncovers a mutually antagonistic mechanism in plant–virus interactions centered on RNA N6-methyladenosine (m6A) modification. The findings reveal how m6A deposition on viral RNA mediates plant antiviral responses, while Cucumber mosaic virus (CMV) deploys countermeasures to suppress this defense, highlighting m6A as a dynamic regulatory battleground with broad implications for RNA-based immunity.

• Marein Restores Chemosensitivity by Inhibiting ABCG2 in MDR

  2026-07-08

  The reference study identifies marein, a flavonoid from Coreopsis tinctoria, as a competitive inhibitor of the ABCG2 transporter, successfully restoring chemosensitivity in multidrug-resistant cancer cells. By targeting a key binding site, marein enhances intracellular drug retention and offers a mechanistic framework for overcoming transporter-mediated drug resistance in oncology.

• Direct Mouse Genotyping Kit Plus: Streamlined Genotyping Wor

  2026-07-08

  The Direct Mouse Genotyping Kit Plus empowers rapid, purification-free extraction and PCR from mouse tissues, accelerating routine and advanced genotyping tasks. Its integrated PCR master mix with dye reagents and optimized buffers cut hands-on time while boosting fidelity—ideal for high-throughput colony screening and transgene validation.

• β-Pseudouridine: Structural Dynamics and Precision in RNA Bi

  2026-07-07

  Explore how β-Pseudouridine, the C-glycoside isomer of uridine, modulates RNA structural dynamics and translational fidelity beyond conventional protocols. This article reveals advanced mechanistic insights and protocol strategies, setting a new benchmark for RNA modification research.

• Prestained Protein Marker: Triple Color Ladder for Reliable

  2026-07-07

  This article addresses practical laboratory challenges in protein analysis—such as reproducibility, assay compatibility, and efficient workflow—using the Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) (SKU F4005). Scenario-driven Q&As provide actionable insights for biomedical researchers, with protocol parameters and referenced evidence, highlighting how this marker streamlines SDS-PAGE and Western blot workflows.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Applied

  2026-07-06

  PYR-41, a potent inhibitor of Ubiquitin-Activating Enzyme E1, is transforming the landscape of protein degradation and immune signaling research. This article offers actionable protocols, advanced troubleshooting, and evidence-backed insights for leveraging PYR-41 in mechanistic, apoptosis, and inflammation assays.

• Ruxolitinib Induces Apoptosis via DRP1 Inhibition in ATC Cel

  2026-07-06

  The reference study uncovers a novel mechanism by which Ruxolitinib phosphate (INCB018424) induces apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) cells through the inhibition of DRP1-mediated mitochondrial fission, downstream of JAK1/2-STAT3 signaling. These findings highlight a previously unappreciated connection between JAK/STAT pathway inhibition and mitochondrial dynamics, presenting new avenues for research in aggressive thyroid cancers.

• Anlotinib in IADSRCT: First Evidence for Multi-Target TKI Ef

  2026-07-05

  This article examines the first reported case of anlotinib hydrochloride—a multi-target tyrosine kinase inhibitor—used as maintenance therapy for metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT). The study demonstrates significant tumor regression and tolerability, offering a new therapeutic perspective for this rare malignancy.

• Immunologically Activated HUC-MSCs Suppress Lung Cancer Grow

  2026-07-04

  This study reveals that immunologically activated human umbilical cord mesenchymal stem cells (HUC-MSCs) inhibit proliferation and metastasis of A549 lung cancer cells, primarily through modulation of PI3K/Akt and NF-κB signaling. The research offers mechanistic insight into the interplay between stem cell immunogenicity and tumor inhibition, suggesting new avenues for cell-based anti-cancer strategies.

459 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page